Enlivex Selected to Present at Israeli BioMed 2025 Conference

About this update from Enlivex Ltd.

[{"type":"image","alt":"Enlivex Therapeutics Ltd","displaySize":"","headline":null,"caption":"Enlivex Therapeutics Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/738648dcca3c88be57f0963407d94f31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lp55OoyoIVpO2pUDVuohlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/738648dcca3c88be57f0963407d94f31","width":150,"height":42}},"lazy":false},{"type":"text","content":"Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases","length":119,"tagName":"p"},{"type":"text","content":"Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company has been selected to present at the upcoming Israeli BioMed 2025 Conference, taking place May 21–23, 2025 in Tel Aviv, Israel. The Company’s presentation is titled “Enlivex—Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases” and will be delivered by the Company’s CEO on May 21st as part of the session “Personalized Pathways; Genetic and Cellular Based Therapies for Rare and Complex Diseases”.","length":635,"tagName":"p"},{"type":"text","content":"Allocetra™, Enlivex’s universal, off-the-shelf cell therapy, is designed to reset macrophages—key immune cells—to their homeostatic, or “balanced,” state. Non-homeostatic macrophages are implicated in a broad range of chronic and life-threatening diseases, and Allocetra™’s unique reprogramming capability may offer a promising strategy for immune system rebalancing and disease resolution.","length":390,"tagName":"p"},{"type":"text","content":"Enlivex is currently advancing a broad clinical pipeline with Allocetra™, including multiple Phase I/II trials in osteoarthritis and psoriatic arthritis. Recent data from a six-month interim readout in moderate knee osteoarthritis showed statistically significant reductions in pain (47%), improvement in joint function (46%), and decrease in stiffness (40%). Additional readouts from ongoing trials are expected in 2025.","length":421,"tagName":"p"},{"type":"text","content":"ABOUT ENLIVEX","length":13,"tagName":"p"},{...

More updates from Enlivex Ltd.